Jean-Charles Soria

Jean-Charles Soria played a central role in the clinical development of durvalumab and the landmark PACIFIC trial establishing durvalumab as standard consolidation therapy after chemoradiotherapy for stage III unresectable NSCLC. The PACIFIC trial demonstrated unprecedented improvement in progression-free and overall survival in stage III NSCLC patients treated with durvalumab after chemoradiation, transforming the standard of care for this patient population. He has led multiple pivotal immunotherapy trials in lung cancer and other tumor types, advancing the clinical development of several checkpoint inhibitors. His translational and clinical research leadership has been central to the expansion of immunotherapy into earlier stages of lung cancer.